Patent Issued for Substituted pyridotriazine compounds and uses thereof (USPTO 11897892).

Gilead Sciences Inc. has been issued a patent for substituted pyridotriazine compounds and their uses in inhibiting the replication of HIV. The patent describes the need for new agents that can effectively suppress the virus and have a decreased potential for drug interactions. The compounds disclosed in the patent have the potential to offer improved pharmaceutical properties, such as improved potency and long-acting pharmacokinetics, which can enhance patient compliance and limit the emergence of drug resistance. The patent includes a list of compounds and their pharmaceutically acceptable salts, as well as claims for pharmaceutical compositions and methods of treating HIV infection. [Extracted from the article]